INOVIO Reports Promising Long-Term Data for INO-3107 in Treating RRP

INOVIO Pharmaceuticals

PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) has announced new data from a retrospective trial showcasing the long-term benefits of its investigational therapy, INO-3107, for patients with Recurrent Respiratory Papillomatosis (RRP). Findings reveal an increase in Complete Response (CR) rates from 28% at the end of an initial 52-week trial to 50% by year two, with further improvement to 54% in year three.

The trial also showed that 95% of participants maintained or improved their Overall Response Rate (ORR) by the end of the second year, with 86% maintaining or enhancing their response by year three. This durability of response supports INO-3107’s potential as a long-term, non-surgical treatment option for RRP.

Dr. Michael Sumner, INOVIO’s Chief Medical Officer, underscored the importance of these results, noting that they provide hope for patients seeking to reduce their reliance on surgery. “Reducing the number of surgeries is of utmost importance,” he said, emphasizing that the data will help guide future re-dosing strategies to further enhance clinical outcomes.

The retrospective trial (RRP-002) evaluated the long-term effects of INO-3107 in 28 patients who had originally participated in a Phase 1/2 trial. The therapy demonstrated no treatment-related serious adverse events throughout this extended follow-up period.

INOVIO plans to submit these findings as part of a Biologics License Application (BLA) in mid-2025. The company also intends to present the data at upcoming scientific conferences and publish results in medical journals.

With INO-3107 showing potential to reduce or eliminate the need for repeated surgeries, company leaders are optimistic about its future role in RRP management. “The data further supports the mechanism of action for INO-3107,” said Dr. Jacqueline Shea, President and CEO of INOVIO, pointing to its ability to activate memory T cell responses that sustain antiviral activity.

READ:  Best Bev Releases Guide on Building High-Performance Sales Teams

The study’s results mark a significant step forward in addressing the needs of RRP patients, offering a path toward improved quality of life and reduced treatment burden.

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.